Analysis index

2 ml citrate plasma (Stability in citrate plasma at 4°C – 8°C: 14 days)

Activity: 79 % – 120 %

Concentration: 210 – 330 mg/l

Evaluation of thrombophilia, suspicion of hereditary antithrombin deficiency, suspicion of acquired antithrombin deficiency in case of liver diseases with decreased protein synthesis, therapy with unfractionated heparin, consumption coagulopathy, HELLP-syndrome, protein loss, i.e. nephrotic syndrome

Acquired causes of antithrombin deficiency are liver diseases, consumption coagulopathy, acute thrombosis, treatment with unfractionated heparin and others. When taking DOAKs (Dabigatran, Rivaroxaban, Apixaban or Edoxaban) evaluation of activity should be sought prior to administering the next dose.

The prevalence of hereditary antithrombin deficiency in the normal population is at 0,2 %. In case of antithrombin deficiency of the heterozygote type, thrombosis risk is increased by about 10 – 20 times. Therefore, antithrombin deficiency belongs to the severe thrombophilias. Following an initial thromboembolic event, patients with a confirmed antithrombin deficiency should receive life-long anticoagulant treatment.